Does Lamotrigine Help With Mania?

Lamotrigine does not help with mania. Across multiple clinical trials and systematic reviews, the drug has consistently failed to show effectiveness against acute manic episodes, and no major treatment guideline recommends it for that purpose. This surprises many people, because lamotrigine is one of the most commonly prescribed medications in bipolar disorder. The disconnect makes sense once you understand what lamotrigine actually does well: it prevents the depressive side of bipolar illness, not the manic side. That distinction matters for treatment decisions in ways worth unpacking.

Why Lamotrigine Fails Against Acute Mania

The evidence here is not ambiguous. A systematic review covering lamotrigine’s use across the lifespan found little or no strong evidence supporting its effectiveness in acute mania.¹ An earlier comprehensive drug review reached the same conclusion: lamotrigine has not demonstrated efficacy in treating acute mania.² A critical review of the literature and treatment guidelines found that antimanic effects simply do not show up in the data, and no guideline examined recommended lamotrigine for mania.³

This lack of antimanic effect makes lamotrigine unusual among mood stabilizers. Lithium, valproate, and several atypical antipsychotics all have demonstrated activity against manic episodes. Lamotrigine sits in a different pharmacological lane. Because it does nothing for mania, guidelines for acute mania note that if someone is already taking lamotrigine for depression prevention, they can continue it, but a second medication will need to be added when mania or severe hypomania breaks through.⁴

What Lamotrigine Actually Does in Bipolar Disorder

Lamotrigine’s real strength is preventing depressive relapse. In an 18-month placebo-controlled trial of people with bipolar I disorder who had recently experienced a manic or hypomanic episode, lamotrigine was significantly better than placebo at delaying the time to a depressive episode. Lithium, interestingly, did not reach significance on that same measure in the same trial.⁵ This is the finding that established lamotrigine’s niche: it stabilizes mood “from below,” preventing the drops into depression rather than capping the highs of mania.⁶

That said, the acute antidepressant evidence is more muddled than most people realize. Across five placebo-controlled trials of lamotrigine for acute bipolar depression, four of the five failed to show a significant difference on primary outcome measures.⁷ The drug’s reputation in bipolar depression rests more on its long-term preventive value than on its ability to pull someone out of an active depressive episode quickly.

How It Works in the Brain

Lamotrigine was originally developed as an anti-seizure medication. Its mood-stabilizing properties were noticed somewhat accidentally when epilepsy doctors observed improvements in their patients’ overall well-being and mood. Psychiatrists then tested it in bipolar patients who had not responded to other treatments, and the drug eventually earned its bipolar indication through a combination of clinical observation and formal trials.⁸

At the cellular level, lamotrigine works by calming overactive neurons. It blocks certain voltage-gated ion channels that control how easily a nerve cell fires, and it reduces the release of glutamate, the brain’s main excitatory chemical messenger. There is also evidence it enhances the activity of GABA, which has an inhibiting and calming effect on brain circuits.⁹ Why this mechanism translates into depression prevention but not mania prevention is not fully understood. One plausible explanation is that the neural circuits driving depressive episodes and those driving manic episodes are not mirror images of each other, so dampening excitatory signaling in a particular way may protect against one polarity without affecting the other.

Lamotrigine Versus Lithium for Maintenance

Because both drugs are used long-term to keep bipolar disorder stable, the comparison between lamotrigine and lithium comes up constantly. The short version: lithium is better at preventing mania; lamotrigine is better at preventing depression. Neither is clearly superior overall, but the balance tilts toward lithium in most head-to-head data.

A Cochrane systematic review found that overall efficacy between the two was similar, with one major exception: recurrence of manic episodes at one year was roughly twice as likely in the lamotrigine group compared to lithium. On the flip side, people on lamotrigine experienced fewer side effects overall.¹⁰ A Danish open-label effectiveness trial found similar results: when manic and depressive relapses were analyzed separately, the trend favored lithium for mania prevention and lamotrigine for depression prevention, though neither difference reached statistical significance individually. That same trial found that almost no patient was maintained successfully on either drug alone after five years.¹¹

A large nationwide observational study painted a more one-sided picture. Compared to lithium, people on lamotrigine were considerably more likely to need an additional psychiatric medication added and were more likely to be hospitalized for both depressive and manic episodes.¹² That study concluded lithium was broadly superior in routine clinical practice. The gap between clinical trial results and real-world data may reflect the fact that lithium’s monitoring requirements (regular blood tests) keep patients more engaged with their care teams.

Using Lamotrigine Alongside Other Medications

Because lamotrigine does not cover mania, many patients with bipolar I disorder end up taking it in combination with another mood stabilizer or antipsychotic. In clinical practice, lamotrigine is combined with an average of about two other psychiatric medications, most often added during periods of stable mood or depression rather than during mania.¹³

One studied combination is lamotrigine plus aripiprazole (an atypical antipsychotic). In a trial of patients who had recently stabilized after a manic or mixed episode, the combination showed a trend toward longer time before manic relapse compared to lamotrigine alone, but the difference narrowly missed statistical significance. Estimated relapse rates at one year were about 11% for the combination versus 23% for lamotrigine alone.¹⁴ The tradeoff was more side effects, including restlessness and weight gain, in the combination group.

The Tolerability Advantage

One reason lamotrigine keeps its place in treatment despite the mania gap is that people tolerate it unusually well compared to alternatives. In cognitive testing, lamotrigine performed significantly better than carbamazepine across nearly half of all measures, spanning reaction speed, memory, and subjective mood, while performing almost identically to taking no drug at all on most cognitive tests.¹⁵ A separate study comparing lamotrigine to valproate in healthy volunteers found that lamotrigine caused fewer cognitive complaints and less sedation. On mood scales, lamotrigine shifted people toward feeling more alert and at ease, while valproate shifted them toward feeling more tired.¹⁶

For many people with bipolar disorder, cognitive dulling and sedation from mood stabilizers are the main reasons they stop taking their medication. Lamotrigine’s lighter cognitive footprint may help explain why, in a real-world follow-up study, about 40% of patients remained on lamotrigine for the long haul, with no withdrawals occurring after roughly a year and a half of treatment.¹⁷ Still, the first month is critical: a quarter of patients in that study dropped the drug within the first four weeks, often before reaching a therapeutic dose.

The Rash Risk

The side effect that gets the most attention with lamotrigine is skin rash. Across 122 randomized controlled trials involving nearly 19,000 patients, about 8% experienced some kind of skin reaction.¹⁸ Most of these are benign and resolve when the drug is stopped or the dose is adjusted. The feared outcome is Stevens-Johnson syndrome, a rare but serious condition where the skin blisters and peels. That same review found the rate of Stevens-Johnson syndrome or the related toxic epidermal necrolysis was 0.04%, or about 1 in 2,500 patients.¹⁸

This is why lamotrigine is started at a low dose and increased very gradually over several weeks. The slow titration schedule is designed specifically to reduce the chance of serious skin reactions.¹⁹ The slow ramp-up has practical consequences for treating mania: even if the drug did work for acute mania, it could not be started quickly enough to help during a manic crisis. This is another reason it sits firmly in the long-term prevention category rather than the acute treatment toolkit.

Drug Interactions That Affect How Well Lamotrigine Works

Two common drug interactions deserve attention because they can dramatically change lamotrigine levels in the blood.

Valproate (another mood stabilizer often used for mania) substantially slows the body’s clearance of lamotrigine, effectively doubling or more the amount of lamotrigine circulating at a given dose.²⁰ This interaction is well known and clinically important: when someone is taking both drugs, the lamotrigine dose needs to be cut roughly in half, and transitioning from one to the other requires careful adjustment over weeks.²¹ Higher-than-intended lamotrigine levels increase the risk of rash and other side effects.

Estrogen-containing birth control pills push lamotrigine levels in the opposite direction. Combined oral contraceptives speed up lamotrigine’s breakdown in the liver, cutting blood levels by roughly half.²² This drop can be large enough to trigger breakthrough mood symptoms. The effect varies by the type of progestin in the pill, with some (like drospirenone and levonorgestrel) reducing lamotrigine levels more than others.²³ Women taking both lamotrigine and hormonal contraception often need dose adjustments, and level fluctuations during the pill-free week of a monthly cycle can add another layer of instability.²⁴

Rapid Cycling and Where Lamotrigine Fits

Rapid cycling refers to having four or more mood episodes in a year, and it is notoriously difficult to treat. Lamotrigine has been studied in this group, with mixed but somewhat encouraging results for the depressive side. In one study, both rapid-cycling and non-rapid-cycling patients improved on depressive and manic symptoms. But among those entering the study in a manic or hypomanic state, rapid cyclers improved less on manic symptoms than non-rapid cyclers. The gap was especially stark in people who started with severe mania, where rapid cyclers showed little improvement at all.²⁵ Maintenance data has been more encouraging for rapid-cycling bipolar II disorder, where depressive episodes dominate the clinical picture and lamotrigine’s depression-prevention strengths are a better fit.⁶

Off-Label Use in Borderline Personality Disorder

Lamotrigine increasingly shows up in the treatment of borderline personality disorder, a condition that shares some surface-level features with bipolar disorder, particularly mood instability and impulsivity. Clinical trials suggest lamotrigine can help stabilize mood and reduce emotional swings in people with borderline personality disorder, with a safety profile comparable to other options.²⁶ This use is off-label and the evidence base is smaller than for bipolar disorder, but the fact that lamotrigine works on emotional dysregulation rather than classic mania may explain why it translates between the two conditions. It is worth noting that mood “instability” in borderline personality disorder is not the same as bipolar mania, and a drug that helps with emotional reactivity does not necessarily help with euphoric or grandiose manic states.

Pregnancy Considerations

For women with bipolar disorder who become pregnant, medication choices get complicated. Lamotrigine is one of the more commonly continued mood stabilizers during pregnancy, partly because alternatives like valproate carry well-documented risks to fetal development. A small retrospective study of women treated with lamotrigine throughout pregnancy found that no women required psychiatric hospitalization and all babies were born alive after 36 weeks, though two had low birth weight and needed intensive care.²⁷ The study was very small (six women), so it cannot tell us much on its own, but it reflects a broader clinical pattern in which lamotrigine is considered one of the safer mood stabilizer options during pregnancy. Because the body clears lamotrigine faster during pregnancy due to hormonal changes, doses often need to be increased and then tapered back down after delivery.

A Rodent Model That Complicates the Story

One piece of data that occasionally confuses the conversation comes from animal research. In a rodent model of mania, where hyperactivity was induced by stimulant drugs, lamotrigine successfully prevented the hyperactive behavior, just as valproate and carbamazepine did.²⁸ This has led some to wonder whether lamotrigine could have antimanic potential that simply has not been captured well in human trials. The explanation probably lies in how poorly animal models reflect the complexity of human mania. A drug that prevents stimulant-induced running in a rat may have little to say about whether it can control the cognitive, emotional, and behavioral storm of a full manic episode in a person. The human clinical data, spanning multiple trials and thousands of patients, consistently says no.